EUCTR2017-003112-39-IE进行中（未招募）1 期
A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals with Bipolar Disorder who are Experiencing a Depressive Episode (SCOPE-BD) - SCOPE-BD
ational University of ireland Galway0 个研究点目标入组 60 人开始时间: 2019年9月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible each participant must meet all of the following eligibility criteria at Screening (Visit 1) and must continue to fulfil these criteria at Visit 2 to take part in the trial:
- •1.Diagnosis of Bipolar Disorder according to Diagnostic Statistics Manual (DSM)-V criteria
- •2.Experiencing an episode of depression of at least moderate severity at Visit 1 (Screening) and Visit 2 based on clinical interview by a trained clinician and a Hamilton Depression Rating Scale (HDRS) score = 14.
- •3.= 18 years old at Visit 2 (male or female)
- •4.In the opinion of the Principal Investigator or Sub Investigator’s, be able and willing to provide written informed consent and to comply with the requirements of this study protocol.
- •5.Written informed consent prior to participating in the study
- •6.U&Es, LFTs and TFTs laboratory tests within acceptable ranges in the previous 4 months of the Screening Visit (Visit 1).
- •Placebo run-in inclusion criteria at Randomisation visit (Visit 3):
- •7. In addition to above participants must be experiencing an episode of depression of at least mild severity (having previously experienced an episode of moderate depression at Visit 2 with HDRS = 14), based on clinical interview by a trained clinician and a HDRS score of = 8.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Participants who meet any one or more of the following exclusion criteria at Screening (Visit 1) or Visit 2 will not be eligible to take part in the trial:
- •1.History of other Axis I diagnosis (including Recurrent Depressive Disorder or Psychotic Disorders such as schizo-affective disorder, conditions that can also present with depressive episodes)
- •2.History in the three months prior to Visit 2 of alcohol dependence syndrome or substance dependence syndrome.
- •3.Current use of oral steroid at Visit 1
- •4.A confirmed diagnosis of dementia
- •5.A diagnosis of intellectual disability (IQ < 70)
- •6.Participants with bipolar disorder that are euthymic in the investigator’s opinion, at screening or Visit 2.
- •7.Participants with bipolar disorder that are hypomanic or manic (Young Mania Rating Scale (YMRS) > 6) at screening or Visit 2.
- •8.Presence of an established neurological disorder or other serious demyelinating conditions as determined by the treating physician (e.g. space occupying lesion, multiple sclerosis)
- •9.Current involuntary detention under the Mental Health Act (MHA) 2001 in an acute psychiatric inpatient unit
- •10.Severity of Bipolar Disorder is such that participation in a clinical trial is not appropriate because of the risk of imminent self-harm (based on clinical note review and review at screening visit by experienced clinician)
- •11.A history of an allergic reaction or sensitivity to Scopolamine (Hyoscine Hydrobromide). Participants will be asked at the screening visit about any previous treatment with scopolamine (Hyoscine Hydrobromide) to ascertain any previous allergic reaction or sensitivity to this agent.
- •12.A clinical diagnosis of narrow angle glaucoma, myasthenia gravis, paralytic ileus, pyloric stenosis, toxic megacolon and acute porphyria.
- •13.Individuals will be excluded from the study if currently prescribed anticholinergic medications including Physostigmine, Biperiden and Procyclidine. Individuals will additionally be excluded if currently prescribed Tricyclic Antidepressants which are associated with significant anticholinergic properties (e.g. Amitriptyline and Nortriptyline) that are currently causing the participant to experience anticholinergic side effects (e.g. blurred vision, constipation, urinary retention, cognitive difficulties). No individuals will have anticholinergic medications stopped to allow them enter the trial.
- •14.Bradycardia < 50 bpm, tachycardia > 100bpm or hypotension (systolic BP <90 and / or diastolic BP < 60) prior to IV administration of placebo or Scopolamine
- •15.A recent history in the last 6 months of symptomatic orthostatic hypotension or syncope.
- •16.Previous participation in this trial. Participation is defined as randomised. Participation in another trial within 3 months prior to Visit 1. Receipt of any investigational medicinal product (IMP) within 3 months prior to Visit 1.
- •17.Participants concurrently being administered Electroconvulsive Therapy (ECT).
- •18.Pregnancy, as determined by a positive urine dipstick at Visits 2, 3, 4, 5, positive blood serum result executed at Visit 2 and confirmed prior to infusion at Visit 3 or participants who are actively breastfeeding (female only).
- •19.Women of child-bearing potential are defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment. Highly effective contraception methods include:
- •Female sterilization (have had surgical
研究者
相似试验
进行中（未招募）
1 期
Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852Parkinson's diseaseEUCTR2011-003866-34-GBorth Bristol NHS Trust (NBT)42
撤回
2 期
Clinical trial to evaluate the effectiveness and safety of Nao Xin Qing (NXQ), a standardised herbal medicine in patients with ischaemic Stroke.Ischaemic strokeStroke - IschaemicACTRN12621000100897Western Sydney University88
已完成
不适用
The Use of Bright Light Therapy in the Treatment of Parkinson's DiseaseParkinson's diseaseNeurological - Parkinson's diseaseMental Health - Other mental health disordersMental Health - DepressionInsomniaACTRN12617001309370The Bronowski Institute of Behavioural Neuroscience Inc30
已完成
3 期
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisCTRI/2016/02/006617Boehringer Ingelheim India Private Limited
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled Trialto Evaluate the Safety and Efficacy of Two DifferentDosages of Phenserine-tartrate in Patients with Mild toModerate Probable Alzheimer’s Disease -Phenserine/APP and AßAlzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking.In addition to the cognitive deficits the patients experience loss of their ability to take care of instrumental activities of daily living, they are not able to meet the most common requirements of daily life and so they are loosing their independence, needing intensive health care in final stages of the disease.MedDRA version: 7.0Level: PrimClassification code 10001896EUCTR2004-001187-52-LVAxonyx Corporation150